TRENDING :  Market Movers  |  Top 50   SPY (0.51%)    XOP (0.56%)    UGAZ (-16.07%)    TVIX (-1.69%)    TSLA (-0.05%)    TQQQ (2.52%)    SPX (0.51%)    SLG (-2.77%)    NTES (3.86%)    NBEV (10.48%)    MU (2.33%)    MA (1.29%)    GS (-0.06%)    FB (1.71%)    EWC (1.11%)    BTCUSD (%)    BOIL (-10.06%)    BIG (-0.37%)    ATVI (0.52%)    AMZN (1.24%)

 CLVS - Clovis Oncology

$20.80 (-3.17%)

Next Earnings



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
JP MorganCory KasimovLowersDowngradesNeutral$16.0010/31/18
Leerink SwannMichael SchmidtAnnouncesInitiates Coverage OnMarket Perform$30.0009/25/18
Stifel NicolausAlex SchwartzLowersMaintainsBuy$110.0002/27/18
RBC CapitalUpgradesOutperform$0.0002/22/18


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher

Clovis Oncology Inc CLVS was a big mover last session as the company saw its shares rise nearly 7 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 46 7 in

Could These Be the Next 2 Biotech Buyouts?

It s been a year of ups and downs for larger biotech stocks but the industry s smaller players have seen a lot of damage The Wells Fargo Biotechnology Small Cap ETF has fallen around 17 in 2018 while the Nasdaq Biotechnology index is right back where it began the year Now

Health Care Sector Update for 12/04/2018: GERN,CLVS,PSTI

Top Health Care StocksTop Health Care Stocks JNJ 1 JNJ 1 PFE 0 78 PFE 0 78 ABT 2 68ABT 2 68 MRK 0 37 MRK 0 37 AMGN 1 26 AMGN 1 26 Health care stocks were mixed in recent trading including a nearly 0 1 gain for the NYSE Health Care Index Tuesday afternoon Shares of health

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

GlaxoSmithKline plc GSK has signed a definitive agreement to acquire small cancer biotech TESARO Inc TSRO for 5 1 billion including the latter s debt The acquisition price of 75 per share in cash represents a premium of 110 to TESARO s 30 day average price Emma Walmsley the U K

Health Care Sector Update for 12/04/2018: CLVS, CRON, MO, PSTI, JNJ, PFE, MRK, ABT, AMGN

Top Health Care Stocks Top Health Care Stocks JNJ FlatJNJ Flat PFE 0 22 PFE 0 22 ABT 0 04 ABT 0 04 MRK FlatMRK Flat AMGN 0 03 AMGN 0 03 Health care stocks were narrowly mixed in Tuesday s pre bell trade Health care stocks were narrowly mixed in Tuesday s pre bell trade

TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

TESARO Inc TSRO announced that it has entered into a definitive agreement with GlaxoSmithKline GSK per which the latter will acquire TESARO s outstanding shares and net debt for 5 1 billion 4 0 billion Glaxo has offered TESARO s investors 75 for each share in cash which represents

Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today

What happened Shares of Tesaro NASDAQ TSRO a mid cap oncology company jumped by as much as 59 on heavy volume this morning after the company announced that it had agreed to a 5 1 billion takeover bid from British pharma giant GlaxoSmithKline NYSE GSK Glaxo

Clovis (CLVS) Up 45.1% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Clovis Oncology CLVS Shares have added about 45 1 in that time frame outperforming the S amp P 500 Will the recent positive trend continue leading up to its next earnings release or is Clovis due for a pullback Before we dive into

TESARO Shares Rally on Rumors of Potential Acquisition Offer

Shares of TESARO Inc TSRO rallied more than 15 on Tuesday on rumors that it may have received a buyout offer According to a Bloomberg report 160 published on Nov 16 the company is working with financial advisers for a potential sale by designing a deal and pursuing prospective

Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up

Clovis Oncology Inc 160 CLVS announced that the United States Patent and Trademark Office has issued a new patent for Rubraca rucaparib The United States Patent 636 issued by the office covers methods of treating cancer with high dosage strengths of Rubraca The patent covers all

Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

Shares of TESARO Inc TSRO and Clovis Oncology CLVS were up on Tuesday after AstraZeneca plc AZN and partner Merck MRK announced that the FDA has granted priority review to their regulatory application looking for label expansion of its PARP inhibitor Lynparza in the first line setting

AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

AstraZeneca plc AZN and partner Merck s MRK supplemental new drug application sNDA looking for label expansion of their PARP inhibitor Lynparza as a first line maintenance treatment for advanced ovarian cancer was accepted by the FDA With the FDA granting priority review a decision